Data compiled by Redley Lamar · ChainSifter Intelligence
2Suppliers
5Customers
3Debt Items
0Related Chains
Source-Backed Evidence Depth
BioRestorative Therapies, Inc. (BRTX) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.
11Total relationships
3Distinct source URLs
8High confidence
0.823Average confidence
2026-09-13Latest database update
ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.
BioRestorative Therapies, Inc. Suppliers
Ticker
Name
Confidence
Evidence
RODMAN-RENSHAW-LLC
RODMAN-RENSHAW-LLC
92%
The Company entered into a placement agency agreement, dated February 11, 2026 (the “Placement Agency Agreement”), with Rodman & Renshaw LLC (the “Placement Agent”), pursuant to which the Company eng…
REGENERATIVE-SCIENCES-LLC
REGENERATIVE-SCIENCES-LLC
90%
we have obtained, among other things, a worldwide (excluding Asia and Argentina), exclusive, royalty-bearing license from Regenerative to utilize or sublicense a certain method for culturing cells
BioRestorative Therapies, Inc. Customers
Ticker
Name
Confidence
Evidence
CUSTOMER
CUSTOMER
92%
The Company's product sales are generated from two product lines: ExoCR, sold to a single customer pursuant to a bill-and-hold arrangement as described below, and BioX, sold to multiple customers wit…
CARTESSA-AESTHETICS-LLC
CARTESSA-AESTHETICS-LLC
85%
we generated $300,000 of cosmetic product sales revenue in connection with our supply agreement with Cartessa Aesthetics, LLC
CALIFORNIA-STEM-CELL-TREATMENT-CENTER-INC
CALIFORNIA-STEM-CELL-TREATMENT-CENTER-INC
62%
ement limitations, and tactical rebranding to avoid FDA enforcement action. FDA lacks the resources to bring enforcement actions against thousands of individual small-office clinics simultaneously. T…
CERTIFICATION-GROUP
CERTIFICATION-GROUP
62%
ement limitations, and tactical rebranding to avoid FDA enforcement action. FDA lacks the resources to bring enforcement actions against thousands of individual small-office clinics simultaneously. T…
STEM-PEARLS-LLC
STEM-PEARLS-LLC
62%
hievements expressed or implied in our forward-looking statements. These risks and factors include, by way of example and without limitation: ● our ability to obtain financing needed to complete our …
BioRestorative Therapies, Inc. Debt Obligations
Instrument
Description
Confidence
Evidence
BRTX-DEBT-8376
Warrants outstanding: 4495038
90%
xbrl warrant detail from xbrl 2025-12-31.
BRTX-DEBT
Debt stack $153,682
90%
Market cache reports total debt of $153,682.
BRTX-DEBT-8377
Xbrl Convertible
90%
xbrl convertible detail from xbrl 2021-12-31.
BioRestorative Therapies, Inc. Acquisitions
No acquisitions on recordNo completed or pending acquisitions found in our database for BioRestorative Therapies, Inc..
BioRestorative Therapies, Inc. Ownership
Holder
Name
Confidence
Evidence
BRTX-OWNER-CITADEL-ADVISORS-LLC
Citadel Advisors Llc
90%
13F overlay lists Citadel Advisors Llc as top holder; 10 tracked holders.
BioRestorative Therapies, Inc. Extended Supply Chain Network
No secondary connectionsNo correlated companies found through shared supply chain relationships.
